Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study

Table 3

Serum levels of TNF- inhibitor in rheumatoid arthritis patients in remission treated with infliximab or adalimumab.

	Anti-TNFi Ab-negative	Anti-TNFi Ab-positive
Infliximab, g/mL	4.7 (2.9–8.0); ( = 25)	1.6 (0.7–4.6); ( = 6)	0.048
Adalimumab, g/mL	9.7 (6.5–11.7); ( = 41)	0.7; ( = 1)

Continuous variables are expressed as medians (interquartile ranges).